The Journal of pharmacology and experimental therapeutics · 2013 · Cell / animal study · PMID 23055539
Explore the library
Preclinical evidenceAngiotensin-IV-derived peptidomimetic
Dihexa
Dihexa is a synthetic peptidomimetic developed from angiotensin-IV-related research. Its cognition-related claims remain grounded primarily in laboratory and animal work.
Also indexed as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
A clear starting point
Dihexa is a synthetic peptidomimetic developed from angiotensin-IV-related research. Its cognition-related claims remain grounded primarily in laboratory and animal work.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
HGF / c-Met
Dihexa is a synthetic peptidomimetic developed from angiotensin-IV-related research. Its cognition-related claims remain grounded primarily in laboratory and animal work.
- Targets & processes
- HGF / c-Met
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Synaptic plasticity and cognitive behavior in experimental models.
What this does not establish
Animal cognition and synapse findings do not establish benefit in human cognitive disorders.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Human safety is not established. HGF/c-Met growth signaling raises unresolved safety questions; FDA has not identified human exposure data for nominated drug products.
Contraindications & cautions
Not an exhaustive contraindication review. Human safety is not established. HGF/c-Met growth signaling raises unresolved safety questions; FDA has not identified human exposure data for nominated drug products.
Medication & supplement interactions
Interaction information is incomplete. Human safety is not established. HGF/c-Met growth signaling raises unresolved safety questions; FDA has not identified human exposure data for nominated drug products.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.